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Background. The intravenous use of voriconazole requires coadministration with sulphobutylether-b-cyclodextrin, which may accumulate in patients with impaired renal function.
Methods. All adult patients treated with the same formulation of voriconazole for a minimum of 3 consecutive days were included. Renal function was assessed based on the creatinine level and the calculated creatinine clearance (CrCl). Change in renal function was calculated on days 3, 7, and end of treatment (EOT) and was defined based on the RIFLE criteria.
Results. Among 166 patients in whom baseline renal function was assessed, 42 (25.3%) had a CrCl ,50 mL/min and received intravenous voriconazole, 77 (46.4%) had a CrCl $50 mL/min and received intravenous voriconazole, and 47 (28.3%) had a CrCl ,50 mL/min and were treated with oral voriconazole. Renal function changed on days 3, 7, and EOT in 19 (11.4%), 14 (8.4%), and 28 (16.9%) patients, respectively. Multivariate analyses identified significant predictors of renal dysfunction: (1) day 3, hematologic malignancy (odds ratio [OR], 5.09, P 5 .01), fluconazole use within 30 days prior to voriconazole (OR, 6.21; P 5 .008), coadministration of penicillins (OR, 6.12; P 5 .03), and immunosuppressants (OR, 7.00; P 5 .002); (2) day 7, baseline liver impairment (OR, 5.30; P value 5 .004); (3) EOT, administration of penicillins (OR, 2.39; P 5 .04).
Conclusions. Voriconazole route of administration and baseline renal function were not predictors of worsening renal dysfunction on days 3, 7, and EOT. Underlying disease, baseline liver impairment, and concomitant administration of other drugs (eg, penicillins, fluoroquinolones, immunosuppressants) were the strongest predictors of renal dysfunction.
Voriconazole is a triazole used for prophylaxis and treatment of invasive fungal infections. The intravenous use of voriconazole requires coadministration with sulphobutylether-b-cyclodextrin (SBECD), which may accumulate in patients with impaired renal function. The voriconazole prescribing information defines patients with impaired renal function as having a creatinine level .2.5 mg/dL or creatinine clearance (CrCl) ,50 mL/min [1, 2] . SBECD, which was developed as a solubilizing agent, is cleared at the glomerular filtration rate. Repeated dose models of SBECD administration to mice and rats yielded dose-related changes in kidney tissue pathology [3] . More specifically, administration of SBECD has been associated with kidney toxicity as a result of renal tubule vacuolation and obstruction in rat models [1, 3] . This appeared to be associated with SBECD administration at higher doses (mild toxicity in rat kidneys was observed with 3000 mg/kg, which is approximately 50-fold greater than the SBECD dose typically administered in humans, whereas doses up to 1500 mg/kg were not associated with any histopathological changes in dog kidneys) and for a longer duration (1-6 months) [1, 4] . Current guidelines suggest that voriconazole should not be administered intravenously to patients with renal impairment, including patients with CrCl ,50 mL/min, or patients who require hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHD) [1, 2] . Instead, administration of voriconazole via the oral route is recommended in these cases. However, oral voriconazole has been associated with lower therapeutic drug levels, treatment failures, and the oral route may not be feasible in some situations [5, 6] . Henceforth, in cases of life-threatening invasive fungal infections, intravenous voriconazole administration may be warranted to ascertain adequate drug levels and optimize the clinical outcome, irrespective of renal dysfunction.
Limited data exist on the safety of intravenous voriconazole in patients with impaired renal function (CrCl ,50 mL/min [7, 8] or requiring HD [4] or CVVHD [9] [10] [11] [12] ). Furthermore, Mohr et al reported that cyclodextrin can be eliminated by HD in patients treated with intravenous itraconazole [11] . In contrast, von Mach et al reported significant accumulation of cyclodextrin in 3 of 4 patients treated with intravenous voriconazole on HD, albeit without any differences observed in the voriconazole-associated adverse reactions [4] . Despite reports of accumulation, it is not clear that cyclodextrin itself actually harms the kidneys in humans [1, 3, 4, 8] .
We hypothesized that intravenous voriconazole may be well tolerated in patients with impaired renal function and can be safely administered. This issue is critically important to resolve, given the known renal toxicities of compounds used as alternatives (eg, amphotericin products). We conducted a retrospective study at 2 academic medical centers in which we sought to assess changes in renal function of patients treated with intravenous or oral voriconazole for 3 days or more.
METHODS
The study was approved by the institutional review boards at The Johns Hopkins Hospital (JHH) and the University of Pittsburgh Medical Center (UPMC). This was a retrospective, observational study of adult (.18 years) patients who were treated with voriconazole using the same route of administration for a minimum of 3 consecutive days. The manufacturer and formulation of voriconazole remained consistent throughout the study period for both institutions and for both routes of administration (intravenous and oral). Patients were identified from the institutions' pharmacy databases. Exclusion criteria included prior administration of voriconazole within 30 days and requirements for HD or CVVHD. In an effort to include only high-risk patients for renal impairment, those with baseline CrCl .50 mL/min treated with oral voriconazole were also excluded. Renal function was assessed based on creatinine and calculated CrCl, using the CockcroftGault formula. Change in renal function from baseline (day 1) was calculated on days 3 and 7 and at end of treatment (EOT) and was defined based on the RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease) proposed by the Acute Dialysis Quality Initiative Group [14] . More specifically, an increase in the serum creatinine .1.5 times baseline or/and a decrease in CrCl by .25% was considered a significant change in renal function [14] . Creatinine was measured with an enzymatic method (Roche Hitachi Modular Analyzer) at JHH and an alkaline picrate reaction at UPMC. Baseline liver impairment was defined as aspartate aminotransferase or alanine aminotransferase .3 times the upper normal limit or/and alkaline phosphatase .2 times the upper normal limit.
Data Collection
The following data were collected: demographics, weight, comorbidities (underlying malignancy, solid tumor or hematologic malignancy, diabetes mellitus, and cardiovascular disease), receipt of a solid organ or hematopoietic stem cell transplant (HSCT), HSCT-related variables (type of transplant, graft vs host disease, and associated treatments), requirement for mechanical ventilation, and administration of antifungal agents within 30 days prior to voriconazole initiation. The creatinine level and CrCl on days 1, 2, 3, and 7 and at EOT were collected. Liver function tests on day 1 (63 days) were recorded. Concomitant administration of the following medications was collected: vasopressors, corticosteroids or other immunosuppressive agents, and antimicrobial agents (aminoglycosides, carbapenems, cephalosporins, colistin, fluoroquinolones, foscarnet, ganciclovir, penicillins, and vancomycin). For vancomycin, duration of administration and vancomycin level (random or trough) during the first 7 days of treatment were recorded when available. For voriconazole, the following variables were collected if available: indication (prophylaxis vs treatment), loading and maintenance dose, route and frequency of administration, start and stop day, and plasma levels.
Statistical Analysis
The primary objective of this study was to assess the rate of renal dysfunction among patients treated with voriconazole for a minimum of 3 and 7 consecutive days of administration of the same formulation of voriconazole. Using logistic regression models, we sought to identify risk factors for renal dysfunction among patients treated with voriconazole based on indicators of change in renal dysfunction between day 1 and day 3, day 7, and EOT. To specifically address the impact of intravenous voriconazole administration in patients with impaired renal dysfunction (CrCl ,50 mL/min) on outcomes, the following variables were added to the univariate analysis: route of voriconazole administration (intravenous vs oral) and baseline renal function (CrCl $50 mL/min vs CrCl ,50 mL/min). In addition, patients were divided into group 1 (intravenous voriconazole with baseline CrCl ,50 mL/min), group 2 (oral voriconazole and baseline CrCl ,50 mL/min), and group 3 (intravenous voriconazole with baseline CrCl $50 mL/min), and pairwise group comparisons were made. Variables that had a P value #.20 in the univariate analyses were introduced into stepwise multivariate logistic regression models to assess risk factors for renal impairment progression adjusted for the other risk factors in the models.
A classification tree analysis was performed for each outcome to identify characteristics of patients with a greater likelihood of renal impairment progression based on the variables included in the multivariate analyses. These subsets were then compared with all other patients using logistic regression analyses to assess the impact of the characteristic combinations on renal impairment progression. Odds ratios (ORs) and 95% confidence intervals (CIs) are presented for all logistic regression analysis results. Statistical analyses were performed using Stata software v 11.1 (StataCorp, College Station, Texas, 2010) and R v 2.11.1 (http://www.r-project.org/).
RESULTS

Baseline Patient Characteristics
A total of 1096 patients were identified who received the same formulation of voriconazole for more than 3 consecutive days. After excluding 930 patients, a total of 166 patients were included in the study population ( Figure 1 ). The baseline patient characteristics are detailed in Table 1 . Among 166 patients, 42 (25.3%) had a CrCl ,50 mL/min and received intravenous voriconazole (group 1), 47 (28.3%) had a CrCl ,50 mL/min and were treated with oral voriconazole (group 2), and 77 (46.4%) had a CrCl $50 mL/min and received intravenous voriconazole (group 3). A total of 109 (65.7%) patients received loading doses of voriconazole at 6 mg/kg twice daily for 1 day. Information on maintenance dose of voriconazole was available for all patients: 47 (28.3%) received a standard dose of 200 mg twice daily, 35 (21.1%) received 2-3 mg/kg twice daily, 72 (43.4%) received 4 mg/kg twice daily, and 12 (7.2%) received 5-6 mg/kg twice daily. Median duration of treatment with voriconazole was 10 days (range, 3-25), 10 days (range, 3-59), and 9 days (range, 2-86) for groups 1, 2, and 3, respectively. Plasma voriconazole levels were available for 27 (16.3%) patients (n 5 10, 5, and 12 for groups 1, 2, and 3, respectively). Eight (29.6%) patients had a level $5 lg/mL: 2 (20%), 1 (20%), and 5 (41.7%) patients in groups 1, 2, and 3, respectively. Patients in group 2 were less likely to have received a loading dose of voriconazole (15 of 47, 31.9%; P , .0001) and more likely to have received voriconazole as prophylaxis (28, 59.9%; P 5 .002), a solid organ transplant (23, 48.9%; P 5 .007), and immunosuppressive agents (25, 53.2%; P 5 .02) compared with the other 2 groups.
The mean (95% CI) creatinine for group 1 on days 1, 3, 7, and EOT was 1.93 (1.75-2.11), 1.93 (1.68-2.18; P 5 .98), 1.55 (1.27-1.83; P 5 .02), and 1.84 (1.57-2.11; P 5 .52), respectively, where P values are for the comparison of day 1 to the other 3 time points (Figure 2 ). The mean (95% CI) creatinine for group 2 on days 1, 3, 7, and EOT was 2.14 (1.93-2.36), 2.19 (1.90-2.47; P 5 .65), 2.07 (1.67-2.48; P 5 .62), and 2.02 (1.63-2.42; P 5 .36), respectively. The mean (95% CI) creatinine for group 3 on days 1, 7, and EOT was 0.87 (.79-.94), 0.93 (.84-1.02; P 5 .01), 0.92 (.76-1.07; P 5 .21), and 1.02 (.84-1.20; P 5 .06), respectively.
Risk Factor Analysis for Renal Dysfunction
Using the RIFLE criteria based on glomerular filtration rate or creatinine level [14] , a change in renal function on days 3, 7, and EOT was observed in 19 (11.4%), 14 (8.4%), and 28 (16.9%) patients, respectively. Univariate analyses to identify risk factors for renal dysfunction on days 3, 7, and EOT were performed using the variables presented in Table 2 . Variables with a P value # .20 on days 3, 7, and EOT were introduced in 3 respective stepwise multivariate logistic regression models ,50 mL/min), group 2 (oral voriconazole and baseline CrCl ,50 mL/min), and group 3 (intravenous voriconazole with baseline CrCl $50 mL/min). a Maintenance dose #4 mg/kg twice a day included: n 5 47 (group 1, n 5 10; group 2, n 5 25; group 3, n 5 12) with 200 mg twice a day, n 5 35 (group 1, n 5 7; group 2, n 5 15; group 3, n 5 13) with 2-3 mg/kg twice a day, and n 5 72 (group 1, n 5 19; group 2, n 5 6; group 3, n 5 47) with 4 mg/kg twice a day. A total of n 5 12 (group 1, n 5 6; group 2, n 5 1; group 3, n 5 5) received .4 mg/kg twice a day. Classification Tree Analysis (Figure 3) For day 3, renal dysfunction was more likely to happen in the following groups: (1) 
DISCUSSION
This is a retrospective observational study that reviewed the renal function of patients treated with voriconazole for a minimum of 3 consecutive days with the same mode of administration. Using predefined criteria to assess significant changes in renal function, the observed rates of change in renal function on days 3, 7, and EOT were 19 (11.4%), 14 (8.4%), and 28 (16.9%) patients, respectively. Based on our findings, baseline renal dysfunction, route of voriconazole administration, or a combination of the above did not impact renal impairment after 3 or 7 consecutive days of administration or at the EOT. In contrast, underlying disease, baseline liver impairment, and concomitant administration of other drugs (eg, penicillins, fluoroquinolones, immunosuppressants) were the strongest predictors of renal dysfunction. Administration of fluconazole within 30 days prior to initiation of voriconazole and concomitant administration of penicillins were identified as major risk factors for renal dysfunction by day 3. As fluconazole and penicillin derivatives are not considered particularly nephrotoxic, we believe that they likely represent an indirect marker of disease severity rather than a direct kidney toxic agent and may have been more routinely administered to higher-risk patients. Patients with an underlying hematologic malignancy were at higher risk of developing renal dysfunction, perhaps as a result of their underlying immunocompromized status and administration of other nephrotoxic compounds including chemotherapeutic agents. The effect of immunosuppressive agents on renal function has been clearly demonstrated, particularly in transplant recipients [15, 16] . In this study, it was not possible to discern whether immunosuppressants led to higher rates of renal dysfunction due to their direct nephrotoxic effect or were just a marker of disease severity. Baseline liver impairment was the strongest predictor of renal impairment in patients treated with voriconazole for at least 7 consecutive days. Baseline liver dysfunction is likely to be an indirect marker of disease severity, suggesting that sicker patients (also requiring treatment with penicillin derivatives) may be at higher risk for developing renal dysfunction. In addition, liver dysfunction may lead to impaired metabolism of other concomitantly administered drugs with potential nephrotoxicity or/and affect renal function via other physiologic pathways. For instance, it has been hypothesized that the reninangiotensin system stimulation due to liver disease may be the mechanism for development of nephrotoxicity in patients treated with aminoglycosides [17] . The impact of liver impairment on renal function was further confirmed with tree classification analyses that demonstrated liver impairment (and administration of penicillins) to be the strongest predictors of renal dysfunction regardless of baseline renal function.
Multivariate analysis at EOT demonstrated that administration of penicillins was the most significant predictor of renal dysfunction, while Caucasian ethnicity was protective. These results were further confirmed by tree classification analyses showing that non-whites treated with penicillins were more likely to develop renal dysfunction. Although penicillin derivatives have been associated with acute interstitial nephritis, we believe that this association may, in part, imply that patients requiring courses of penicillin drugs might have been sicker (as an indirect marker of disease severity) and hence more likely to develop renal impairment. In fact, white patients with baseline liver impairment treated with penicillins appeared to be at high risk for renal function deterioration. Consistent with prior reports, we observed that non-whites were more susceptible to such changes, perhaps associated with higher rates of hypertension and diabetes mellitus or genetic factors [18] [19] [20] [21] .
In univariate analyses, voriconazole blood level $5.0 mcg/mL was found to be significantly associated with worsening renal function at EOT. Voriconazole levels were available for only 27 patients, limiting our ability to make definitive conclusions. As voriconazole is extensively metabolized in the liver, hepatic impairment may lead to higher concentrations of voriconazole and associated toxicities. An elevated voriconazole level has been associated with increases in total bilirubin, aspartate aminotransferase, and alkaline phosphatase [22] [23] [24] [25] [26] . To our knowledge, creatinine and voriconazole level have been correlated in 1 study, although creatinine did not retain statistical significance in multivariate analyses [27] .
Administration of vancomycin for $7 days and vancomycin levels $15 mcg/mL have been strongly associated with renal dysfunction [28] [29] [30] [31] . Renal dysfunction was not associated with vancomycin use, duration of vancomycin administration, and high vancomycin levels ($20 mcg/mL) in this study. Although more than half of the patients received vancomycin concomitantly with voriconazole, the effect of vancomycin on renal function might have been diluted due to the overall small number of patients included and stronger associations with other variables. In addition, vancomycin levels were available for a minority of patients only, which prevented preventing us from making further conclusions. A major limitation of this study was the small number of patients included. Patients were not comparable in terms of several characteristics across the 3 groups to allow for more in-depth analyses. Hence, the observed results may be skewed due to the small number of patients included and may underrepresent all 3 groups. A limited number of patients continued voriconazole for $7 days, preventing us from making any significant conclusions for that time endpoint. It is likely that longer voriconazole courses may lead to cyclodextrin accumulation; albeit, we were not able to assess this effect in our study. Finally, different assays were used for creatinine measurement in the institutions involved in this study. As the alkaline picrate reaction has a variance structure, this assay may have more interference and lead to less accurate results.
In conclusion, we report that a small subset of patients treated with voriconazole develop renal dysfunction. We did not observe an impact of administration of intravenous voriconazole in patients with baseline CrCl ,50 mL/min on deterioration of renal function after 3 or 7 consecutive days of administration. Although clinicians should be cautious when treating patients with renal dysfunction with intravenous voriconazole, weighing the risks and benefits of such an intervention is usually made at the bedside while considering a multitude of variables including the severity of infection being treated and general state and prognosis of the patient. Prospective studies will be required to definitively address the impact of intravenous voriconazole on the kidneys in patients with impaired renal function. Figure 3 . Classification tree prediction models for day 3 (A), day 7 (B), and end of treatment (C ). Subsets of patients with higher likelihoods of Figure 3 continued. renal dysfunction were compared with all other patients to identify the strength of the combined characteristics. A classification tree analysis was performed for each outcome to identify characteristics of patients with a greater likelihood of renal impairment progression based on the variables included in the multivariate analyses. These subsets were then compared with all other patients using logistic regression analyses to assess the impact of the characteristic combinations on renal impairment progression. In the classification tree analysis diagrams, the terminal nodes are portrayed by rectangles. Only the statistically significant terminal nodes are presented in this figure with the associated odds ratios and P values for renal dysfunction. A, The classification tree had a total of 25 nodes (13 were terminal nodes), and 10 major predictors were selected. The first level of the tree was split into 2 initial branches based on the duration of voriconazole administration, which was the best predictor of renal dysfunction. B, The classification tree had a total of 19 nodes (10 were terminal nodes), and 8 major predictors were selected. The first level of the tree was split into 2 initial branches according to baseline liver impairment, which was the best predictor of renal dysfunction. C, The classification tree had a total of 15 nodes (8 were terminal nodes), and 7 major predictors were selected. The first level of the tree was split into 2 initial branches according to administration of penicillins, which was the best predictor of renal dysfunction. Abbreviations: CreCl, creatine clearance; IV, intravenous; OR, odds ratio; PO, oral; VOR, voriconazole.
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